Actively Recruiting
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Led by Tzu-Fei Wang · Updated on 2025-12-17
50
Participants Needed
4
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts. The investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 2 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 30 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy for these patients.
CONDITIONS
Official Title
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older with active cancer diagnosed or treated in the past 6 months, or with progressive or relapsed cancer
- Confirmed blood clot diagnosed within the last 14 days requiring treatment with blood thinners
- Platelet count below 50,000 per microliter due to cancer or cancer therapy
- Able to provide written informed consent
You will not qualify if you...
- Receiving blood thinner treatment for the current blood clot with platelet count below 50,000 per microliter for more than 72 hours
- Only superficial vein thrombosis
- Life expectancy less than 1 month as judged by the doctor
- Kidney function with creatinine clearance less than 30 ml/min
- History of heparin-induced low platelet counts
- Low platelet counts caused by other conditions like thrombotic microangiopathy, immune thrombocytopenia, or disseminated intravascular coagulation
- History of platelet transfusion not working due to specific antibodies
- Refusal to accept blood products
- Blood thinner treatment is unsafe due to active bleeding or bleeding disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
University of Alberta
Edmonton, Alberta, Canada
Withdrawn
2
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
3
Niagara Health - St. Catharines Site
Saint Catharines, Ontario, Canada
Actively Recruiting
4
Windsor Regional Hospital
Windsor, Ontario, Canada, N8W 1L9
Actively Recruiting
Research Team
J
Jennifer Brinkhurst
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here